-
Safety and efficacy of low-dose dasatinib in elderly patients with newly diagnosed chronic myeloid leukemia in chronic phase
Time of Update: 2022-04-30
The DASISION clinical trial showed that patients with newly diagnosed CML in the chronic phase treated with the second-generation TKI dasatinib (100 mg/day) had higher rates of major molecular remission and faster remission rates compared with patients treated with the first-generation TKI imatinib Fast; nearly half of patients had deep molecular remissions lasting at least 1 year without relapse after discontinuation of dasatinib .
-
A simple new prognostic stratification system can effectively predict the prognosis of newly diagnosed multiple myeloma patients
Time of Update: 2022-04-30
In univariate analysis, both ISS stage III and elevated LDH were associated with increased risk of death in patients and were therefore included in the final multivariate with high-risk IgH translocation, MYC rearrangement, 1q amplification, and chromosome 17 abnormality in the model .
-
Disruption of the lung microbiome may explain why some children do poorly after stem cell transplants Science Translational Medicine
Time of Update: 2022-04-30
Click the blue text above to follow us A new study of 104 children finds that disruption of the lung microbiome may explain why some children with blood cancers and other blood diseases tend to have lower survival rates after stem cell transplants .
-
2022 EBMT China Voice Compared with sibling congruent transplants, haploidentical transplants achieve better quality of life without compromising survival
Time of Update: 2022-04-30
Recently, an increasing number of patients have achieved better survival by receiving haploidentical transplantation (HID HSCT), but it remains unclear whether the long-term quality of life (QoL) of these patients is comparable to that of patients receiving sibling-identical transplantation (MSD HSCT) quite .
-
What is the prognosis of allogeneic hematopoietic stem cell transplantation in 2022 EBMT elderly patients with acute myeloid leukemia?
Time of Update: 2022-04-30
Table: Patient Characteristics at Transplant Study Conclusions The study results demonstrate the feasibility of haploidentical allo-HSCT in AML patients over 70 years of age, and no serious complications were found.
-
Frontier bleeding rate reduced by 84%, hemophilia A gene therapy Phase 3 clinical results listed on NEJM
Time of Update: 2022-04-30
▎WuXi AppTec content team editors Today, BioMarin Pharmaceutical announced that the results of the Phase 3 clinical trial of the gene therapy valoctocogene roxaparvovec for the treatment of severe hemophilia A were published in the prestigious medical journal The New England Journal of Medicine .
-
2022 EBMT Research progress of ruxolitinib in the treatment of graft-versus-host disease
Time of Update: 2022-04-30
OS10-03 Title: Comparison of the efficacy of ruxolitinib and best available therapy in the treatment of hormone-refractory aGVHD: a post hoc analysis of remission in different involved organs in the REACH2 study Background of the multicenter, randomized phase 3 clinical trial REACH2 ( NCT02913261) showed that in patients with hormone-refractory aGVHD, ruxolitinib improved overall response rate (ORR) at day 28 and durable ORR at day 56 compared with best available therapy (BAT) (key secondary end point; 39.
-
2022 What is the status of EBMT hematopoietic stem cell transplantation in the treatment of peripheral T-cell lymphoma?
Time of Update: 2022-04-30
A total of 39 patients received autologous hematopoietic stem cell transplantation (ASCT) as consolidation therapy, 10 after first remission, 20 after second-line therapy, and 8 after third-line therapy .
Nineteen patients with a more aggressive PTCL course underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) at first transplant (n=14) or after ASCT failure (n=5).
-
2022 EBMT Celebrities Comment on Professor Huang Wenrong: Research Progress of Autologous Hematopoietic Stem Cell Transplantation for Consolidation Treatment of PCNSL
Time of Update: 2022-04-30
S. Cernauskiene et al conducted a retrospective study of patients receiving consolidation therapy with ASCT following induction therapy with HD-MTX, rituximab (Rtx), cytarabine (AraC), and thiotepa (TT) regimens.
-
[Nature sub-issue] New technology - "MAESTRO" improves the detection of cancer DNA in blood, reducing the amount of sequencing by 100 times!
Time of Update: 2022-04-30
Current technologies require extensive sequencing to find low-abundance mutations of DNA fragments, a research team at MIT and Harvard has developed a new technique called MAESTRO that can accurately and efficiently identify thousands of DNA mutations in patient blood samples with a small amount of sequencing .
-
Can veneclax be used for the treatment of patients with relapsed/refractory Waldenström macroglobulinemia?
Time of Update: 2022-04-30
The study found that two genes, MYD88 and CXCR4, have highly reproducible somatic mutations in WM patients, and these mutations can affect the disease performance, prognosis and response to BTK inhibitor therapy .
-
First CLL patient to receive CAR T-cell therapy reaches 10-year complete remission
Time of Update: 2022-04-30
Komaroff, MD Two Cases of Aggressive CLL Patients Long-term complete remission was achieved after receiving CAR T-cell therapy .
Comments CAR T-cell therapy has achieved complete remission at 10 years in at least two patients with aggressive CLL .
-
What is the prognosis of allogeneic hematopoietic stem cell transplantation in 2022 EBMT patients with primary myelofibrosis?
Time of Update: 2022-04-29
Abstract number: P572 Title: Allogeneic hematopoietic stem cell transplantation in myelofibrosis: a single-center retrospective study in Spain Methods The investigators conducted a retrospective study and analyzed the correlation between overall survival of patients after allo-HSCT ( OS) related variables .
-
Guidelines Overview Chinese Guidelines for the Diagnosis and Treatment of Thrombocytopenic Purpura (2022 Edition) (1)
Time of Update: 2022-04-29
Thrombotic thrombocytopenic purpura (TTP) is a rare and severe thrombotic microangiopathy whose main clinical features include microangiopathic hemolytic anemia (MAHA), thrombocytopenia, neuropsychiatric symptoms, fever, and renal failure.
Clinically, patients who completely conform to the typical "pentad" of TTP are relatively rare, and the "triad" with MAHA, thrombocytopenia and neuropsychiatric symptoms is more common.
-
Fixed-duration therapy with ibrutinib combined with veneclax has excellent efficacy in newly diagnosed CLL patients
Time of Update: 2022-04-29
Here, the investigators report the results of the primary analysis of the CAPTIVATE FD cohort of fixed-duration first-line treatment of CLL/SLL with ibrutinib plus veneclax .
-
2022 EBMT Cladribine combined with busulfan/cyclophosphamide conditioning regimen for autologous hematopoietic stem cell transplantation in acute myeloid leukemia
Time of Update: 2022-04-29
Cladribine (CLAD) combined with other drug pretreatment can reduce the recurrence rate and improve overall survival after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologically unresolved AML .
-
How to manage MM bone disease?
Time of Update: 2022-04-29
Chinese Society of Clinical Oncology (CSCO) 2021 MBD expert consensus recommendation [3]: ordinary X-ray examination of skull and long bones of limbs; CT examination of rib lesions, including WBLD-CT; 18F-fluorodeoxyglucose positron emission tomography Scan-CT (18F-DG PET-CT) is helpful to know whether there is extramedullary plasmacytoma and minimal residual disease (MRD) detection; MRI is suitable for cervical, thoracic, lumbar, pelvic lesions and spinal cord compression examinations (evidence level : H; Recommended level: A) .
-
2022 EBMT Voice of China TBI conditioning regimen can improve survival in patients with T-LBL treated with allo-HSCT
Time of Update: 2022-04-29
) showed that the cumulative recurrence rate (CIR) at 1 and 5 years after allo-HSCT in T-LBL patients was significantly lower than that in auto-HSCT (32% vs 46%, respectively, P=0.
The results suggest that a TBI-based regimen can reduce the risk of recurrence and improve survival in adult high-risk T-LBL patients .
-
Patients with functional high-risk multiple myeloma have worse clinical outcomes
Time of Update: 2022-04-29
Based on this, the criteria for evaluating patients with FHR were more precisely defined to include only patients who did not respond well to treatment or who progressed within 12 months of starting induction therapy without any clinically applicable high-risk genetic features .
-
JCO (IF=45) Xu Kailin's team from Xuzhou Medical University found that the combination of B cell maturation antigen and CD19 CAR-T cells is safe and effective in the treatment of multiple myeloma
Time of Update: 2022-04-29
The combination of iNature anti-B cell maturation antigen (BCMA) and anti-CD19 chimeric antigen receptor (CAR) T cells induces high response rates in relapsed or refractory (R/R) multiple myeloma (MM) patients, but Long-term outcomes have not been assessed .
